Impact Therapeutics will invest the cash from the Lilly Asia Ventures-backed round to further develop its lead cancer treatment candidate.

The critical care data analytics technology developer was founded in 2017 and has its system in testing on 200 hospital beds in the Michigan Medicine centre.

The psychiatric and cognitive disorder drug developer secured the financing in a round backed by its founder, PureTech Health.

Corporate VC units GE Ventures and Sanofi Ventures both invested to help the health behaviour tracker take its funding to $61m altogether.

Cigna, HCSC and Novo have taken part in a $50m funding round for MDLive, a telehealth platform already backed by Sentara and Sutter Health.

Verana Health, a life sciences product development platform spun out from Stanford and formerly known as DigiSight, has received funding from GV and GE Ventures.

Verana Health, a life sciences product development platform formerly known as DigiSight, has received funding in a GV-led round featuring GE Ventures.

After taking the role on an interim basis a year ago, Evan Facher is now permanent director of Innovation Institute in addition to vice-chancellor for innovation and entrepreneurship.

Antiviral drug developer ReViral has secured series B funding in a round co-led by Novo Ventures that included Brace Pharma Capital.